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imag(in)ing
		
Scientists at Yale and around the world are
challenging the laws of physics as they seek
			 new ways to peer ever more deeply into
		
the workings of the human body.
ALSO

4 A Nobel for discoveries in cell transport / 6 Yale’s 23rd president takes the helm / 46 Fight against gene patenting

ON THE COVER Fluorescent dyes and confocal
microscopy produced
this image of brown
adipose tissue (BAT), also
known as brown fat,
one of two types of fat
tissues found in mammals. BAT burns lipids (a
group of molecules that
include fats) in order to
generate heat. The tissue
was stained with dyes
that bind either to lipids,
which appear green in
the image; or to the endothelial cells that make
up blood vessels and
appear red. The stained
tissues were imaged
using fluorescent confocal microscopy, which
detects the fluorescent
dyes individually. In the
final stage, the images of
each dye were merged
to create this composite.
Staining and confocal
microscopy are among
the key tools used by
Yale scientists as they
seek ways to look ever
more deeply into the human body.
INSIDE COVER A similar
process involving fluorescent dyes and confocal microscopy produced
this image of white
adipose tissue (WAT),
commonly known as fat
tissue. WAT is the major
repository for lipids in the
body and requires high
vascularization, shown in
red dye, in order to take
up lipids from the blood
after a meal.

Scientific images
provided by Ryan Berry
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From dead cells to live movies

New light microscopes developed by Yale cell biologists are helping
researchers unravel the complexities of human biology. By Ashley Taylor
22/

Can brain scans reveal how we think?

Scientists debate whether such higher-order processes concepts as
consciousness and morality have their own real estate in the brain.
By Jenny Blair, M.D. ’04
33/

	Inside the toolbox

An inside glimpse at the School of Medicine’s five core research
facilities that allow biological visualization on the atomic, molecular,
and cellular scales. By Amanda Alvarez

36/

A new vision in the lab and in the clinic

Since the discovery of X-rays in the 19th century, new imaging
technologies have helped physicians peer into the causes of disease.
By John Dillon
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Editor
John Curtis

A new vision for Yale Medicine
The magazine in your hands or on
your computer screen or tablet is
the first that reflects a new design
and vision for Yale Medicine. As
we announced in our Spring
issue, in addition to a redesign
of the magazine, we focus our
feature stories on a single topic
in medicine, science, or medical
education. The theme for this
inaugural issue is biomedical
imaging, in which we explore the
ways in which biologists have
endeavored to peer ever more
closely at the molecular underpinnings of life. You can also visit
our website at yalemedicine.yale.
edu, or download an iPad version
at yalemedicine.yale.edu/app or
by scanning the QR code at right.
We hope you enjoy this issue and
those to come.
John Curtis
Editor, Yale Medicine

S E C ON D O PI N I ON
BY S I D N E Y H A R R I S

We would like to offer our
thanks to these faculty and
alumni who have served on the
Yale Medicine Advisory Board for
their counsel and insights over
the past few years. We have
benefited greatly from their
participation in the planning of
the magazine:
Sharon L. Bonney, M.D. ’76;
Irwin M. Braverman, M.D.’55,
HS ’56; Sharon A. Chekijian,
M.D. ’01; John A. Elefteriades,
M.D.’76, HS ’81, FW ’83; Rupali
Gandhi, J.D. ’00, M.D.’04;
Owen D. Garrick, M.D.’96;

Robert H. Gifford, M.D., HS ’67;
Elliott Levy, M.D. ’87; Raymond
J. Lynch, M.D. ’05; Kavita
Mariwalla, M.D. ’04; Bruce
L. McClennan, M.D.; Gregory
S. Raskin, M.D. ’98; Asghar
Rastegar, M.D.; Lisa Sanders,
M.D. ’97, HS ’00; Vinita Takiar,
M.D. ’10, Ph.D. ’10; Karl G.
Wagner Jr., PA-C ’90; and
Warren D. Widmann, M.D. ’61,
HS ’67. And we offer a special
thanks to Michael Kashgarian,
M.D. ’58, HS ’61, FW ’65, for his
service as editor-in-chief of Yale
Medicine, which began in 1986.
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dialogue

T H I S I S S U E O F YA L E M E D I C I N E is devoted to bioimag-

ing technology. In our feature section we explore the history of biomedical imaging and examine how scientists at
Yale are developing new ways of seeing smaller and smaller
structures. Advances in imaging technology over the last
several decades have enabled an ever more detailed view of
the internal structures of organisms as well as their functions,
from the level of molecules and cells to that of tissues, organs,
and body. The pace of technological development is rapidly
increasing, with the result that we can now see, in high resolution, things that we could only guess at before. Below, Dean
Robert J. Alpern, M.D., discusses the importance of imaging
in science and medicine and what the future may bring.
When we talk about imaging at Yale School of Medicine, what does
that encompass? Imaging includes everything from crystallography to microscopy at the highest resolution, to X-rays, CT
scans, MR, SPECT, and PET. It’s any technology that allows us
to visualize biologically relevant structures and processes.

ROBERT LISAK PHOTO

Why is it important? A rate-limiting factor in science now is
access to the latest technology. For instance, our ability to understand how the brain functions is presently limited by the availability of technologies that allow us to measure the function of
individual neurons, parts of neurons, and even molecules within
each specific neuron. Traditionally, the best medical schools
invest in the best scientific talent and then equip those individuals with the best available technology. We’re investing in a
third element, which is research in new technologies, so we can
advance the state of the art. We want our scientists to invent the
new technologies, which is already happening.
How will imaging change science and medicine in the future? One
way is the example that I alluded to earlier. I think the functional
definition of all the circuits in the brain will come only from
improved technologies in brain imaging. Another area where
it might help is the use of imaging to identify new biomarkers.
For instance, right now we’re very good at using imaging to see
if someone has prostate cancer. But can we tell if the prostate
cancer is the type that needs to be taken out because it’s going
to metastasize? Or if it’s the one that’s going to sit there and not
metastasize? If you combined spectroscopy with imaging, by
studying the metabolism of those cells, could you find something
that determines whether they’ll metastasize? If you could, you
would spare many patients unnecessary treatment, and you
would lower health care costs at the same time. These are benefits that would accrue across medicine and science.

chronicle
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A Nobel Prize for
studies of cell trafficking
AS HE NEARED THE END

of the day in October

that began with an early-morning phone call from
Sweden, James E. Rothman, Ph.D., recalled before
a gathering of his colleagues, students, and university leaders what he described as an “out-ofbody experience”—the news that he had shared in
the 2013 Nobel Prize in physiology or medicine.
CLOCKWISE FROM TOP LEFT

P H O T O S , C L O C K W I S E F R O M T O P L E F T: T E R R Y D A G R A D I , M I C H A E L M A R S L A N D , T E R R Y D A G R A D I

Dean Robert Alpern and
President Peter Salovey
praised Nobel laureate James Rothman’s
persistence in pursuing
research into vesicles
that transport material
between and within cells.
At a press conference
in the Historical Library,
James Rothman, shown
with his wife, Joy Hirsch,
described receiving the
news that he had won
a Nobel as an “out-ofbody experience.”
Rothman told assembled
journalists that vesicle
trafficking is essential to
many biological processes, including cell division
and insulin secretion.
It is also important in
the nervous system,
passing on messages
that govern movement,
perception, cognition,
memory, and mood.

“I have gotten close to 1,000
e-mails,” said Rothman, the
Fergus F. Wallace Professor of
Biomedical Sciences and professor
and chair of cell biology, speaking at a reception in the Beinecke
Rare Book and Manuscript Library
on the evening of October 7.
“You hear from all kinds of people: someone who practiced
medicine with my father, a third
grade classmate.”
Earlier in the day at a press
conference he said he was still
absorbing the news. “It’s a little
hard to believe all this is happening,” he said. Rothman noted his
good fortune in having studied at
Yale and learning “to appreciate
science and intellectual activity
at its highest, to have matured
and started my career as a
researcher when your idea was
the only limit. Any risk could be

taken, no matter how difficult. I
was fortunate to have taken a few
of those risks and today’s Nobel
Prize recognizes the success that
came out of that.”
The prize acknowledged his
contributions to the understanding of membrane trafficking,
the means by which proteins
and other materials are transported within and between cells.
Rothman, a 1971 Yale College
graduate who previously shared
in the Albert Lasker Award for
Basic Medical Research, the
Louise Gross Horwitz Prize of
Columbia University, and the
Kavli Prize in Neuroscience, is
one of the world’s foremost
experts on exocytosis, a form
of trafficking in which cargobearing spheres called vesicles
fuse with cell membranes to
deliver their contents.
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nobels at yale
George E. Palade, Ph.D.,
who served on the Yale
faculty from 1973 to
1990, and was the first
chair of cell biology,
shared the 1974 Nobel
Prize in physiology or
medicine with Albert
Claude, Ph.D., and
Christian de Duve, Ph.D.
The prize was granted
for “for their discoveries concerning the
structural and functional
organization of the cell.”
Palade’s innovations in
electron microscopy
laid the foundations of
modern cell biology.
Sidney Altman, Ph.D.,
Sterling Professor of
Molecular, Cellular,
and Developmental
Biology and professor
of chemistry, shared
the 1989 Nobel Prize in
chemistry with Thomas
R. Cech, Ph.D., “for their
discovery of catalytic
properties of RNA.”
Thomas A. Steitz, Ph.D.,
Sterling Professor of Molecular Biophysics and
Biochemistry, professor
of chemistry, and investigator, Howard Hughes
Medical Institute, shared
the 2009 Nobel Prize in
chemistry with Venkatraman Ramakrishnan,
Ph.D., and Ada E. Yonath,
Ph.D., “for studies of the
structure and function of
the ribosome.”
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This process is essential to
such processes as cell division and
insulin secretion, for example,
but also plays a crucial role in the
nervous system. Vesicles carrying neurotransmitters fuse with
cell membranes at synapses and
pass on chemical messages that
govern movement, perception,
cognition, memory, and mood.
For three decades, Rothman has
performed experiments that have
revealed the molecular machinery of membrane trafficking in
fine detail. In much of his work
Rothman sidestepped the complexities of working with complete cells by using a “cell-free”
approach—isolating the intracellular components crucial to membrane trafficking.
Rothman and the two scientists who shared in the $1.2 million award—Randy W. Schekman,
Ph.D., of the University of
California−Berkeley, and Thomas
Südhof, M.D., of Stanford
University—all faced skepticism
within the scientific community
when they began their research.
Each went on to solve a different
piece of the puzzle.
While Rothman figured
out the machinery underlying membrane trafficking,
Schekman discovered a set of
genes essential for vesicle traffic, and Südhof determined
how vesicles know when and
where to release their cargo.
Rothman began his research
career after receiving his Ph.D.
from Harvard in 1976. From there
he went on to the Massachusetts
Institute of Technology, Stanford,

Princeton, Memorial SloanKettering, and Columbia before
coming to Yale in 2008.
“When Jim started his career,
a number of successful biochemists were recognizing the
importance of studying molecular
processes in cell-free systems,
but no one imagined that you
could study vesicle trafficking in
a cell-free system,” said Robert
J. Alpern, M.D., dean and Ensign
Professor of Medicine, at the press
conference. This bold approach
revolutionized the field.”
“Yale is absolutely thrilled
to have one of our most distinguished faculty—who is also
one of our most distinguished
alumni—receive this great
honor,” said President Peter
Salovey, Ph.D., the Chris Argyris
Professor of Psychology.
—Charles Gershman
and John Curtis

»

Yale celebrates its
23rd president
In his more than 30 years at Yale,
Peter Salovey, Ph.D. ’86, has been
a student, scholar, psychologist,
and scientist. Over those years he
has risen through the university
hierarchy—serving as chair of
psychology, Yale College dean,
provost, and now, president.
His tenure became official on
October 13 with his inauguration as Yale’s 23rd president. In
the week leading up to the ceremony, Yale celebrated with a
reception for faculty and staff,

a parade of dogs including Yale
mascot Handsome Dan, an open
house, and a panel of university
presidents who offered their
cumulative wisdom. Salovey,
the Chris Argyris Professor of
Psychology, also visited 27 schools
and departments across Yale. His
penultimate visit brought him to
the medical school, where he has
longstanding collaborations in
research in cancer and HIV/AIDS.
As a social psychologist, he is best
known for developing the concept
of emotional intelligence with
colleague John D. Mayer, Ph.D.
The roles he has filled
throughout the university have
given him a sense of community that infused his inaugural
address, in which he vowed to
continue to “bring Yale to the
world and the world to Yale.”
On the stage in Woolsey Hall,
flanked by his predecessor
Richard C. Levin and dignitaries
including New Haven Mayor John
DeStefano Jr., Salovey noted the
achievements of Levin’s 20-year
tenure. Many reflect engagement
with the broader world: a strong
partnership with the city of New
Haven, more than 900 faculty
members engaged in overseas
projects, and Yale’s emerging status as a global institution.
Salovey said that he would
develop a university that is both
more unified and more global and
ensure that Yale remains accessible to “brilliant, hard-working,
and committed applicants who
would invigorate our campus
and improve our world.” He
promised to “support, expand,

Yale’s new president,
Peter Salovey, greeted
well-wishers during a
procession from Woolsey
Hall to a block party on

Hillhouse Avenue. The
university’s task, he said
in his inaugural address,
is to “retain the ties that
bind us together …”

»
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How Cold War nuclear
testing launched the field
of DNA repair at Yale

and celebrate basic and problemdriven research in the fields of
today and those of tomorrow.
“Our task,” he said, “even
while we grow in size, even
while we commit to being a
more diverse faculty, staff, and
student body; more cross disciplinary; and more global, is
to retain Yale’s focus on the ties
that bind us together, the sense
of being a small, interdependent
community, but one with an
impressively broad scope. This
intimacy and shared sense of
purpose is what generates Yale’s
distinctive spirit.”
Glad tidings added to that
sense of unity in the days leading up to his inauguration: A
1954 Yale College alumnus gave
Yale College the largest gift in
its history—$250 million; James
Rothman, Ph.D., chair of cell
biology and an alumnus of Yale
College, shared in the 2013 Nobel
Prize in physiology or medicine,
and the football team kicked
off the season with a 3-0 winning streak. (The day after his
inauguration Salovey had more

good news to share: Robert J.
Shiller, Ph.D., Sterling Professor
of Economics, had won the Nobel
Prize in economic science.)
But being part of a larger
community allowed him to birg,
a term from social psychology
that stands for bask in reflected
glory. “You identify with something bigger than yourself, like
Yale; then, when something
good happens to someone else
in that organization, your selfesteem goes up. Jim Rothman
won the Nobel Prize—that
reflects on me!” Salovey said.
“If you can identify with something bigger than yourself and
‘bask in reflected glory,’ you
can feel pretty good about other
people’s successes. This is the
key to happiness. … This is what
makes this place so wonderful.”
—John Curtis

In the 1950s, U.S. Senator
Prescott Bush, a Republican
from Connecticut and father and
grandfather to future presidents,
approached Yale’s biophysics
faculty with a request. Could
they determine whether radiation causes irreparable damage
to human DNA?
World War II had just ended
with the first strategic use of
atomic weapons. The Soviet
Union and the United States were
locked in a Cold War arms race.
Scientists and the public alike
feared that radiation from nuclear
testing would cause irreparable
DNA damage and cancer—a belief
that grew out of the illness and
death in the aftermath of the
atomic bomb blasts in Japan.
The Atomic Energy Commission
(AEC) countered that people
exposed to equivalent doses of
radiation exhibited different outcomes; while some developed
cancers, others didn’t. It was
premature, the AEC concluded,
to say that the effects of radiation
were irreversible.
The search for answers was
on. Yale biophysics and radiobiology researchers began to
study the effects of radiation on
living cells. “The time was ripe
and the situation was ideal,”
recalled Philip Hanawalt, Ph.D.
’59, then a graduate student
in the biophysics department.
“Watson and Crick had just
reported the structure of DNA,

Winter 2014

7

chronicle

online exclusives
Med school alum nominated as surgeon general.
Med student’s research
recognized at a cancer
conference.
A lesson from a Nobel
laureate.
How the medical school
is recruiting minority
faculty.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our homepage at
yalemedicine.yale.edu.
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and biophysicists at Yale decided
it was important to learn what
radiation did to DNA.”
Hanawalt and other researchers reflected upon those
heady times in May, when the
Department of Therapeutic
Radiology hosted a symposium
to commemorate 50 years of
DNA repair research at Yale.
Hanawalt, who holds the Dr.
Morris Herzstein Professorship
in Biology at Stanford, recalled
an all-hands-on-deck mentality
among the biophysics faculty.
“We met weekly for informal
research discussions. We were like
a large family sitting around the
table discussing science. We were

all focused on a common goal,
figuring out what radiation did to
cells, and particularly to DNA.”
In their search for answers
Yale scientists made many of the
pioneering discoveries in the
field of DNA repair. Researchers
in the Radiology Department, a
precursor to the Department of
Therapeutic Radiology, and in
biophysics discovered not only
DNA repair mechanisms but
also their genetic control. The
research that began at Yale led,
Hanawalt said, “to an understanding of the multiple DNA
repair mechanisms required for
the maintenance of genomic stability in all living cells.”
The formal discovery of DNA
repair occurred in three laboratories simultaneously. Hanawalt’s
graduate research with Richard
Setlow, Ph.D. ’47, initiated studies
on the inhibition and recovery of
DNA synthesis in bacteria following irradiation with ultraviolet
light. Then Setlow subsequently
found, mutant cells that were
sensitive to ultraviolet light
retained damage in their DNA,
while normal cells cut out the
damage. Hanawalt had moved
to Stanford, where he showed
that repair patches were inserted
into DNA, presumably replacing
the damaged parts that had been
removed. At Yale, Paul HowardFlanders, Ph.D., isolated mutant
bacteria sensitive to ultraviolet
light and reported that while normal bacteria removed the damage,
the mutant bacteria could not.
Damage in DNA, the researchers
concluded, can be cut out and the
missing parts replaced correctly
through a process called nucleotide excision repair.
Joann Sweasy, Ph.D., professor of therapeutic radiology and

of genetics, pointed out that
DNA repair occurs naturally in
our cells every day. “But if the
repair isn’t good, or there’s a
faulty gene, that’s when you get
suboptimal mutations that lead
to cancer,” she said.
Peter Glazer, M.D. ’87,
Ph.D. ’87, chair and Robert E.
Hunter Professor of Therapeutic
Radiology, professor of genetics, and member of the faculty
advisory committee of the Cancer
Biology Institute at West Campus,
has overseen a $9 million grant
from the National Cancer Institute
titled “DNA repair in cancer biology and therapy.” The title suggests an important goal for the
field of DNA repair. The grant,
which ended June 30, was to take
advantage of knowledge of DNA
repair pathways in order to treat
cancer. The interdisciplinary
effort brought together more than
a dozen investigators to focus on
fundamental and translational
cancer biology.
“The DNA repair field is getting more and more exciting
in its complexity and its relevance to human health,” said
Hanawalt. “If you Google DNA
repair, you’ll get more than
18 million hits. It’s alive and
well, and the early insights of
radiation biologists at Yale got it
started, while current scientists
at Yale help to keep it in orbit.”
—Jennifer Kaylin

A R T: T H I S PA G E (C L O C K W I S E F R O M T O P L E F T ) , H A R O L D S H A P I R O P H O T O , I S T O C K P H O T O . C O M P H O T O S (3) ; O P P O S I T E PA G E , F R É D É R I C B E N A G L I A I L L U S T R AT I O N

a collection of recent
scientific findings

INFLAMMATION
& DISEASE

PATHWAY TO
NEW ARTERIES

Everybody knows what happens when we get hurt or
infected. The injured part
of our body swells. That’s
our innate immune system
offering a short-term fix by
attempting to restore the
proper physiological balance.
But that quick fix may also be
a root cause of many serious
disorders, according to Ruslan
M. Medzhitov, Ph.D., and
Richard A. Flavell, Ph.D. The
two immunobiologists have
proposed a unifying theory
to describe how inflammation can affect the body’s
homeostatic control mechanisms to trigger the onset of
disease. Now Medzhitov, the
David W. Wallace Professor of
Immunobiology and a Howard
Hughes Medical Institute
(HHMI) investigator, and Flavell,
chair of the department of
immunobiology, Sterling
Professor of Immunobiology,
and an HHMI investigator, will
have a chance to test their
theory of inflammation and
chronic disease, thanks to
a $10 million grant from the
Blavatnik Family Foundation,
the charitable organization
headed by American industrialist and philanthropist
Len Blavatnik. The grant will
support the scientists’ efforts
to define the molecular links
among inflammation, commensal microorganisms, and
chronic disease.

Scientists at the School of
Medicine and University
College London (UCL) have
found a molecular pathway
that can bypass blocked
arteries and help form new
arteries after heart attacks,
strokes, and other acute illnesses. The Yale-UCL team
reported in the April 29
issue of Developmental
Cell that in order to make
new arteries, which can
form in adults when organs
become oxygen-deprived,
three molecules must work
together. The oxygen-starved
organs must first release a
molecular signal called VEGF.
That signal must then bind
with two molecules known
as VEGFR2 and NRP1. NRP1
transports the other two
molecules to a signaling
center in the walls of blood
vessels. Mice that lacked part
of that transporter had poorly
constructed arterial branches
in their internal organs and
could not repair blood vessel blockage by forming new
arteries. “This opens new
therapeutic opportunities for
developing drugs that would
either stimulate or inhibit
blood vessel formation,” said
corresponding author Michael
Simons, M.D. ’84, professor
of medicine and cell biology,
and director of the cardiovascular research center at the
School of Medicine.

MELANOMA SURVIVORS USING TANNING BEDS
About a quarter of those who
have survived melanoma
leave the sunscreen at home
on sunny days, and some survivors still use tanning beds,
according to research by Yale
Cancer Center (YCC) that was
presented at the American
Association for Cancer
Research Annual Meeting
2013 in Washington, D.C. Both
tanning beds and unprotected sun exposure raise the
risk of life-threatening skin

cancer. Using data from the
indoor tanning bed during the
National Health Interview
previous year. “It’s incredibly
Survey, conducted annually
disturbing that even after
by the Centers for Disease
getting the disease once,
Control and Prevention, the
some survivors continue
Yale team found that most
these practices, which would
of a sample of 171 melanoma
put them at greater risk of
survivors were taking pregetting it again,” said author
cautions, but 15.4 percent
Anees B. Chagpar, M.D.,
said that they rarely or
M.P.H., associate professor of
never stay in the shade;
surgical oncology at YCC and
27.3 percent said that they
director of the Breast Center
never wear sunscreen when
at Smilow Cancer Hospital at
they’re outside on sunny days Yale-New Haven.
for more than an hour; and
2.1 percent reported using an

CANCER PATIENTS: QUIT SMOKING
It may seem like a no-brainer,
but Yale Cancer Center experts and the American Association for Cancer Research
(AACR) are calling on doctors
to advise their patients to quit
smoking after being diagnosed with cancer—any cancer. Patients who smoke have
worse outcomes than those
who quit, and quitting smoking improves the efficacy of
cancer treatments, reduces

risk for future cancers, and
enhances rates of survival.
This is true for many cancers,
not just lung cancer. The
experts made their call in a
statement released at the
AACR Annual Meeting 2013 in
Washington, D.C. “It is crucial
that all oncologists in any
setting both assess tobacco

use and take ownership of
ensuring that their patients
receive appropriate treatment
for their tobacco use,” said
Benjamin A. Toll, Ph.D., associate professor of psychiatry,
director of the smoking cessation program at Yale Cancer
Center, and chair of the committee charged with writing
the AACR policy statement.
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imag(in)ing
		 Scientists at Yale and around the world are
challenging the laws of physics as they seek
			 new ways to peer ever more deeply into
		
the workings of the human body.
SINCE THE IN V EN TION OF THE MICROSCOPE in the 1700s, scientists

have struggled to find new ways to peer deeper and deeper into the human
body to look at smaller and smaller cells and organelles. Constrained for
centuries by a law of physics, they began to find ways to overcome what is
known as the diffraction limit only in the 20th century. New technologies
now allow scientists to see things on a scale once thought impossible, and
the knowledge gleaned from those views is helping clinicians find new
ways to care for patients. In this issue of Yale Medicine, we explore the
ways in which Yale investigators and physicians are pushing the frontiers
of imaging technology in a search for answers to human biology and disease. Our lead story by Ashley Taylor, “From dead cells to live movies,”
looks at super-high-resolution microscopy, which has advanced cell biology by offering real-time glimpses of what one scientist calls “cellular fireworks.” John Dillon interviewed a neurosurgeon, a diagnostic radiologist,
and a urologist who work with scientists to improve care for their patients
through new imaging techniques. Jenny Blair delved into the debate in
neuroscience over the mind and the brain: Can scientists determine your
political, moral, or philosophical leanings based on an fMRI scan of your
brain? And Amanda Alvarez described core imaging facilities at the School
of Medicine that provide access to new technologies.

/ 12 From dead cells to live movies / 22 Can brain scans reveal how we think? 	

E L I Z A B E T H J A M E S O N S O L A R P L AT E E T C H I N G : VA L E N T I N E (D E TA I L)

“Valentine,” by Elizabeth Jameson, is a Solarplate
etching on paper that shows a coronal view of her
brain stem, cerebellum, and lateral ventricles. In
her art, Jameson said in her artist’s statement, she
celebrates the beauty, complexity, and mystery
of the brains of individuals who, like herself, have
one of the most common neurological diseases of
the human body, multiple sclerosis.

/ 33 Inside the toolbox

/ 36 A new vision in the lab and in the clinic

from
dead
cells
to live
movies
New light microscopes developed by Yale cell
biologists are helping researchers unravel the
complexities of human biology.
By Ashley Taylor

SCIENTIFIC IMAGE PROVIDED BY PIETRO DE CAMILLI

Pietro De Camilli, who studies how brain cells
package neurotransmitters, used electron
tomography to capture this 3-D image that
shows what happens when the process goes
awry. Vesicles about 40 nanometers in diameter (blue) deliver neurotransmitters between
cells by fusing with the outer membranes of
neurons. Normally, after they release their

cargo, vesicles are recycled and take on more
neurotransmitters for another shipment.
When the protein dynamin is mutated, this
recycling does not occur and vesicle buds
(green) that cannot be released to generate
new vesicles accumulate at the cell surface
and its infoldings.

chair of Yale’s newly formed
cell biology department, shared a Nobel Prize in physiology or medicine for
using electron microscopy to elucidate the inner workings of cells—groundbreaking findings that some say ushered in the modern field of cell biology.
But although the electron microscope opened new avenues of research, it
had a huge drawback as a tool for studying life: it can observe cells only after
they are dead, treated with special fixatives, and sliced into thin sections
or coated in a layer of metal. The grayscale world pictured in such detail
in electron micrographs, while powerful, is “a cellular cemetery,” in the
words of Pietro De Camilli, M.D., FW ’79, the Eugene Higgins Professor of
Cell Biology, professor of neurobiology, and director of the Yale Program in
Cellular Neuroscience, Neurodegeneration and Repair.
I N 19 74, T H E L AT E G E O RG E E . PA L A D E , P H . D.,

Because electron microscopy’s vision is limited to dead
cells, it provides just a snapshot of a cell’s inner workings. Derek K. Toomre, Ph.D., associate professor of
cell biology, likes to compare an electron micrograph of
a cell to a still photograph taken during a football game.
If you are trying to learn the rules of the game, Toomre
said, a snapshot doesn’t get you very far. The same is
true in biology. “There are a lot of biological problems
that—if you could see them in living cells in action—we
would be able to unravel.”
To observe live cells, scientists use light microscopy,
which includes the dissecting microscopes familiar
from high school biology and extends to high-tech
microscopes whose images brighten the pages of scientific journals.
But standard light microscopy too has a major
limitation in resolution: scientists have known since
the 19th century that it cannot resolve, or distinguish
between, structures smaller than about the size of
organelles. Smaller structures—the vesicles carrying
cellular messages and the protein scaffolding that gives
cells their heft and shape—blur together because of
what is called the diffraction limit, described in 1873
by Ernst K. Abbe, a contemporary of the microscope
manufacturer Carl Zeiss.
A light microscope, even with an excellent lens, cannot resolve structures smaller than about half the wavelength of the light used to illuminate them. That works
out to a resolution of about 250 nanometers, around the
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size of the measles virus and about 400 times smaller
than the width of a strand of human hair.
In trying to learn the rules of cell biology’s game,
scientists had at their disposal detailed still images
from the electron microscope and views of the cell in
action from the light microscope, with some of the
most interesting players too small to see. Although
each type of microscope had its uses, between them lay
a large gap.
In the last 20 years, however, scientists have found
ways to overcome the diffraction limit and close that gap
through what is called super-resolution light microscopy. Using custom-made fluorescence microscopes,
some designed by Yale scientists, researchers at Yale are
observing the live-cell dynamics of structures that they
could previously see only in snapshots. With these new
data, they are beginning to answer scientific questions
nearly as old as the limit that once held them back.
“This is the direction in which we have to go,” said
De Camilli, who studies how brain cells package
neurotransmitters, the chemicals that pass along neuronal signals. “Super-resolution microscopy is really
the next critical step.” Gesturing toward a photo on
his wall of a smiling Palade, who looks as though he’s
listening in on our conversation, De Camilli continued,
“Palade was a pioneer in the use of electron microscopy.
We feel like super-resolution microscopy is the next
frontier in microscopy, and we think it’s appropriate
that it happen here, in the heritage of George Palade.”

RO B ERT LI SAK PH OTO, SC I ENTI FI C I MAG ES PROVI D ED BY PI E TRO D E C AM I LLI

c ellu l a r f i re wo rk s

Joerg Bewersdorf, Ph.D., assistant professor of cell biology and of biomedical engineering, “stumbled into
microscopy” in 1996. Then an undergraduate studying physics at the University of Heidelberg, Bewersdorf
wanted to develop technologies that would help scientists in other fields. After taking an optics class with
Stefan W. Hell, Ph.D., who, Bewersdorf said, was then “a
junior professor, not really known, just a very dynamic
person,” Bewersdorf joined Hell’s new lab at the Max
Planck Institute for Biophysical Chemistry
in Göttingen, which was quite small at
the time. “Eight years later, when I left,”
Bewersdorf remembers, “the lab had like
35 people, Hell was famous and had won a
lot of awards, and this whole field of superresolution microscopy had taken off.”
Hell, director of the institute since 2002,
had broken the diffraction limit, building a microscope that allowed scientists to
see tiny biological structures in a way not
thought possible. For years Abbe’s diffraction limit had been considered dogma, with
scientists skeptical of attempts to bypass
it, Bewersdorf said. Breaking the limit
required a change in the way scientists
thought about microscopy.
“To really break the diffraction limit,
you can’t think of the microscope as just
optics,” said Bewersdorf. “And this is
what people had done for 150 years—it
was always about lenses or it was always
about light.” Instead, said Bewersdorf, Hell
was thinking about the interaction of the
microscope light with the cells or tissue being examined. Hell believed that resolution could be improved,
not by modifying the light used to make a sample fluoresce but by altering the fluorescent light as it is emitted.
Using this approach, Hell theorized in a visionary 1994
paper in the journal Optics Letters that he would be able
to achieve a resolution of 35 nanometers—small enough
to see not just organelles but structures within them,
like the involutions of the mitochondria, the cell’s power
plants, or the many layers of the Golgi apparatus, the
cell’s protein-processing pipeline.
By 1999, Hell had built a super-resolution microscope. His new technique was called stimulated emission
depletion (STED) microscopy. A year later his lab showed
that STED could work with biological material. In 2006,
other research groups independently published papers

TOP “This is the direction in
which we have to go,” said
Pietro De Camilli. Highresolution imaging technologies can overcome the
diffraction limit that held back
advances in cell biology for
many years. De Camilli, shown
here with a TIRF microscope,
uses the new imaging modalities to study how brain cells
package neurotransmitters.
MIDDLE Epifluorescence microscopy produced this image
of synapsin (green spots on
the surface of two neurons)
and adaptin (in red). These two
proteins play a role in forming
and storing neurotransmitterfilled synaptic vesicles at sites
where neurons communicate. Comparing the staining patterns of synapsin and
alpha-adaptin—under different
conditions of neuronal activity
and/or after pharmacological
and genetic perturbations—allows researchers to assess the
status of synaptic vesicles and
their recycling. Shawn Ferguson,
who produced this image, noted
that it “does not boast a high
degree of resolution—hundreds
of nanometers.”
BOTTOM De Camilli and his
collaborators used superresolution microscopy to
create these images of vesicles
being reformed. The color images show the location of two
proteins, dynamin and clathrin,
involved in that process. “We
are zooming in at incredible
levels of resolution,” he said.
The color images were taken
with fluorescence microscopy
and the other image was taken
with electron microscopy.
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TOP A split image of microtubule structures shows
the advantage of a super-resolution pointillism
technique called fPALM/STORM over traditional
imaging methods. Thousands of images of fluorescent molecules are taken and reassembled by
computers. Microtubule structures are important in
processes ranging from maintaining cell structure
to providing platforms for intracellular transport.
ABOVE This is not your grandparent’s microscope. In
their efforts to obtain images of smaller and smaller
structures, scientists have moved away from lenses
and light to such complex and sophisticated devices
as this STED microscope, which relies on fluorescence and laser beams. Joerg Bewersdorf trained in
physics, but now works with cell biologists looking
for images of ever-smaller cellular structures.
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Diffraction limited image

Super-resolution Image
5 µm

describing a different approach to light microscopy that
achieved even higher resolution than Hell’s technique.
Each group gave its version of the technique a different
name: photoactivated localization microscopy (PALM);
fluorescence photoactivated localization microscopy
(fPALM); and stochastic optical reconstruction microscopy (STORM). All three versions, however, rely on the
same principle—imaging a fluorescently labeled sample
a few scattered points at a time. By 2012, scientists were
using the term “diffraction-unlimited microscopy,” or
even “nanoscopy,” to reflect the fact that these new
microscopes work on the scale of nanometers. The paradigm shift was complete.
At about the time that Hell was developing his new microscope, from 1997 to 2001,
Toomre was also in Germany (though he did
not meet Bewersdorf until they both came to
Yale) as a postdoctoral fellow at Heidelberg’s
European Molecular Biology Laboratory.
Toomre was trying to learn about vesicles, the
bubble-like structures that cells use to shuttle
materials in and out and from one cellular
location to another. Vesicles are ubiquitous
in biology—they transport everything from
hormones to neurotransmitters. In the brains
of animals, signals pass from one neuron to
another thanks to a process called exocytosis, in which vesicles packed with neurotransmitters fuse with the cell membrane of
one neuron and empty the chemicals into the
synapse—the space between it and the next
neuron—to transmit the message. (James
E. Rothman, Ph.D., the Fergus F. Wallace
Professor of Biomedical Sciences and professor
and chair of cell biology, shared in the 2013 Nobel Prize
for physiology or medicine for his studies of vesicles.)
“I was frustrated,” said Toomre, “because we knew
biochemically that these things had to go out to the
surface, and we could see these little vesicles moving, but we really didn’t see them fuse.” He had tried
to simulate vesicle fusion in a test tube, an effort that
failed after a year. But he had heard about a microscope
called a total internal reflection fluorescence (TIRF)
microscope that might help. The TIRF microscope
could selectively illuminate objects in a thin 80nanometer optical section and achieve much higher
resolving power than traditional confocal microscopes
—but only near the surface of the cell. The technology
was perfect for observing the fusion of a vesicle with
the cell membrane. Toomre “begged and pleaded” to

Breaking the diffraction limit
The period at the end of this sentence is 1 million
nanometers wide. With super-resolution microscopy, scientists can see synaptic vesicles as small
as 30 nanometers wide. Imagine taking a picture
of the continental United States from the stratosphere and being able to distinguish a single strand
of hair.
Fluorescent tags make this possible. Molecules
and structures of interest are given a fluorescent

tag—either a dye or a genetically engineered tag
like green fluorescent protein (GFP). A laser beam is
directed at the target sample, which makes the tag
emit light, and the resulting fluorescence is recorded
to create an image.
The first fluorescence microscopes scanned
an entire sample at once, which produced a fair
amount of out-of-focus fluorescence. Today’s standard fluorescence microscope—the confocal microscope—scans a sample one point at a time, pixel by
pixel, and assembles the pixels to create an image.
The size of each fluorescent point in these standard
microscopes is determined by how much the laser
light diffracts and is limited by the diffraction limit
to between 200 and 250 nanometers.
Stefan Hell’s innovation, STED, improves resolution by reducing the size of each fluorescent spot.
STED targets the light returning from the sample
and a second laser blocks out the fluorescence in a
donut shape around the center of each fluorescent

spot. Each fluorescent point is reduced to the size
of the donut hole. These smaller points of light
yield a higher-resolution image. STED microscopy
can achieve a resolution of 25 to 80 nanometers,
small enough to distinguish cellular vesicles and
the folds within organelles.
PALM/fPALM/STORM capture just a few scattered molecules at a time so that they are unlikely
to overlap and blur together. Using labels that turn
on and off, scientists arrange to have only a few
molecules fluoresce at one time; then they take
a picture. A computer finds the center of each
spot, representing a single fluorescent molecule,
on the individual photo. This process is repeated
thousands of times, and the photos are then combined. The approach is sometimes called pointillist
microscopy, after Impressionist Georges Seurat’s
painting technique. Pointillist techniques achieve
extremely high resolution, about 25 nanometers. However, the technique can also be slow—it
requires many photos to generate one image, and
it is dependent on high-powered computers to
process the data.
TIRF microscopy, developed in the early 1980s,
excites fluorescence in a thin layer near the cell
surface, which reduces background fluorescence
and improves resolution to between 40 and 100
nanometers. TIRF microscopy is faster than pointillist techniques but has lower resolution and can
record only the cell surface.
These are only a few of the high-resolution
microscopy techniques available today, and Yale is
unusual in that it has all these microscopes—STED,
PALM/fPALM/STORM, the electron microscope,
and others—in one place, said Derek Toomre. Each
has its strengths and weaknesses. “If we knew
that there was one type that could do everything,
we wouldn’t be investing in all of them. … There’s
no clear winner. We’ll see; maybe there will be.”
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The magnitude of advances in microscopy becomes clear in the context of its
four-century history.

Seeing the unseeable
Starting around the turn
of the 17th century, natural philosophers using the
light microscope saw
things where, to the naked
eye, there was nothing
to see. The Englishman
Robert Hooke observed
pockets of air within cork,
which he called cells; the
Dutch scientist Anton van
Leeuwenhoek saw living
bacteria in pond water
and cells within blood
and even found “wee
beasties,” as he sometimes called his “cavorting”
specimens, in his own semen.

Electron microscope
In the 1930s, the German physicist Ernst Ruska developed a
microscope with ultra-high
resolution by using electrons,
which have a smaller wavelength than light and can distinguish tinier features. Using
Ruska’s new electron microscope, scientists could view
structures within an individual
cell, with the downside that they
could not look at live cells.
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n e w f ro n t i er s … i n bi o lo g y

Bewersdorf, one of the first physicists recruited to the
highly interdisciplinary Department of Cell Biology at
Yale, joined the faculty in 2009 because he wanted to
collaborate with biologists who were using these new
microscopes to answer important questions in biology.
A burning question both within and outside the
department: How does the Golgi apparatus, the cell’s
protein processing plant, work? A stack of membranebound disks, the Golgi processes proteins into their final
forms, adding sugar and phosphate molecules as they
pass from one end of the stack to the other and are sorted
to other areas of the cell. If necessary, the Golgi packages
them into vesicles to be released from the cell. For 100
years, Toomre said, scientists have debated whether the
Golgi is a stable structure that moves vesicles around or a
dynamic structure that transforms itself into the vesicles
it releases. The debate continues, as a major roadblock is
the inability to see small vesicles trafficking within the
highly convoluted Golgi “pancake” in live cells. Now, by
labeling both the Golgi and the proteins moving through
it, then watching the labeled cells at super-resolution, an
international consortium of researchers at Yale, Oxford,
and Cambridge are hoping to find the answer.
Vesicles are also a focus of De Camilli’s lab, which is
studying the way they are made. Vesicles are formed
by pinching off from a larger membrane, like the cell
membrane or the membrane of an organelle. De Camilli
wanted to know which proteins are responsible for
cutting the new vesicle off from its parent membrane.
Two proteins might be involved, he thought: clathrin
and dynamin. He wanted to see where the two proteins are located on the vesicle. In his office, De Camilli
draws furiously on a scrap of paper: green for clathrin,

TERRY DAG R AD I PH OTO, SC I ENTI FI C I MAG E PROVI D ED BY DAN I EL B I EM ESD ERFER

“Cavorting
wee beasties”

borrow the TIRF microscope in the lab of cell physiologist Wolf Almers, Ph.D., who was then at the Max
Planck Institute. “Within a few hours of imaging,” said
Toomre, “we had an amazing result. We could see these
vesicles arrive and explode during fusion.” In 2000,
Toomre, Almers, and others published their observations in The Journal of Cell Biology. This was Toomre’s
entrée into super-resolution microscopy, which he
would pursue at Yale beginning in 2001.
In his office, Toomre shows a more recent video generated by a TIRF microscope of fluorescently labeled
vesicles fusing with the cell membrane. Fluorescent
green dots—the vesicles—move around on the screen,
then flash brightly as they fuse with the cell membrane.
“It’s fireworks,” Toomre said. “Cellular fireworks.”

gray for dynamin. Under regular light microscopy,
clathrin and dynamin seem to overlap. To demonstrate
this overlap, De Camilli draws green and gray swirls,
one atop the other. But using super-resolution microscopy, he shows me that dynamin is clearly distinguishable from clathrin.

SCIENTIFIC IMAGE PROVIDED BY DEREK TOOMRE, ROBERT LISAK PHOTO

… i n m ed i c i n e …

The new information about cell structure revealed by
super-resolution microscopy is helping scientists to
understand the mechanisms of diseases that affect
humans, De Camilli said—in particular, diseases rooted
in genetic mutations. Many genetic disorders, he said,
result from changes in the distribution or localization
of proteins in cells. “In order to understand in which
way the mutation affects cell function, it is very useful
to be able to localize either the mutant protein itself or
organelles and proteins with which it interacts or the
organelle on which it is localized,” De Camilli said.
For example, De Camilli is studying Lowe syndrome,
a rare disorder that almost exclusively affects males and
causes intellectual disability, congenital cataracts, and
kidney problems. His previous research had revealed that,
on the molecular level, Lowe syndrome causes problems with endocytosis, the process by which a vesicle
empties its contents into a cell. Using super-resolution
microscopy to monitor the distribution of the normal and
mutant Lowe syndrome proteins on endocytic vesicles,
De Camilli hopes to better understand the mechanisms of
the disease, with implications for therapy.
Toomre is using TIRF microscopy to study diabetes
by watching the way fat cells respond to insulin. When
fat cells are stimulated with insulin, he has found,
vesicles whose membranes contain sugar transport
proteins rush to the cell membrane and fuse with it,
adding the transporter proteins to the cell membrane
and allowing the fat cells to take up more glucose. In
diabetes, this process is somehow disrupted, and
Toomre hopes to find out how. So far, he said, “Using
this TIRF microscopy, we discovered that there were
two different types of vesicles arriving at the surface,
and until we could see it, we didn’t realize that.”

… a n d i n t ec h no lo gy

On the cellular level, the Golgi apparatus is the new frontier. In the lab, this new frontier is studded with giant
microscopes enclosed in black boxes to keep out light
and prevent temperature fluctuations. Bewersdorf walks
me through his lab. His custom-made STED microscope
looks in part like other confocal microscopes I’ve seen,

TOP Throughout his career Derek Toomre has tried
to learn more about vesicles, structures that move
proteins, neurotransmitters, and other cargo in
and out of cells and from one cellular location to
another. This composite image, taken with dualcolor live-cell epifluorescence microscopy, shows
vesicles moving along microtubule “highways.”
ABOVE Toomre believes that seeing cells in real
time is crucial to understanding human biology.
“There are a lot of biological problems that—if you
could see them in living cells in action—we would
be able to unravel.”
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In 1873, the Italian physician and scientist Camillo
Golgi stained neurons using a silver compound that
turned the cells black. The Spanish neuroanatomist
Santiago Ramón y Cajal put Golgi’s method to fruitful
use, making observations that led to the
neuron doctrine, the now-accepted idea
that the nervous system is composed
of discrete cells. In 1886, Paul Mayer
invented the hematoxylin and eosin
staining procedure. Hematoxylin stains
cell nuclei blue; eosin is nonspecifically
attracted to proteins and gives the rest
of the cell a contrasting reddish hue.
The most important dyes used in light
microscopy today, however, are fluorescent.

Fluorescence microscope
Though the fluorescence microscope was invented
around 1910, fluorescence microscopy did not really
take off until the end of the century, spurred by the
development of fluorescent labels for specific biological structures.
The most famous
of these fluorescent tags is called
green fluorescent
protein, or GFP,
a protein derived
from jellyfish that
emits green light
when stimulated
by blue light. [For more on the use of marine life
as a source of fluorescent tags, see “In coral reefs,
a treasure trove of tools” on next page.] In the
1990s, scientists isolated the gene encoding GFP,
which allowed them to engineer cells genetically
so that GFP could be fused to a protein of interest
for visualization with the fluorescence microscope.
Microscopy’s palette expanded as scientists developed variations of GFP that fluoresce in different
colors; and by labeling different structures with different fluorescent molecules that can be visualized
at the same time, scientists can determine whether
those structures are colocalized and potentially
interacting. Fluorescent labels are not limited to
proteins: they can also label DNA, lipid molecules,
and carbohydrates. And efforts to break the diffraction limit would increasingly rely on these fluorescent proteins.
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with eyepieces and a computer screen displaying an
image. But nearby is a table with black sides reminiscent
of a filled casket. Inside are black tubes with white labels,
lined-up lenses of different tints, and blue and silver
cables. The laser beam, he said, travels through the blue
cables; the fluorescence travels to the detector through
the silver ones. What’s good about these custom-built
microscopes, Bewersdorf said, is that he can easily adjust
them for different samples.
“A lot of the things at the edge are not commercial.
A lot of the microscopes that you’ll see in Joerg’s lab
are custom-made,” said Toomre, “and they’re custommade because that’s the only way you can do it.”
Bewersdorf has achieved his goal of working with
scientists in other fields, and the number of scientists
who can thank him is likely to grow. “Super-resolution
is something that just about everyone is trying to
jump into,” said Michael W. Davidson, Ph.D., a Florida
State University scientist who is collaborating with
Bewersdorf and Toomre by providing fluorescent proteins from his large collection. “It’s had a huge impact,
but I think the impact is just starting. I think almost
everybody’s going to be doing it within 10 years.”
Bewersdorf and Toomre are working with microscope companies to commercialize the instruments that
they have custom-built in their labs. For now, though,
this is what Toomre calls “the edge,” the frontier of science. I asked Bewersdorf if he thought the resolution of
light microscopy would continue to improve. “No,” he
said. The goals are no longer about resolution. Now the
challenges are finding compatible fluorescent labels
in order to watch multiple structures simultaneously
and developing cameras that can capture the images
faster and faster to create videos of cellular structures in
motion. Perhaps the most important challenge is to apply
this technological tool kit to questions of neuroscience,
metabolism, and cancers whose answers may be central to human health. Bewersdorf shows me a pointillist
microscope, also custom-built in his lab. That microscope,
armed with a digital camera, can take photos so fast that
they can be used to create high-resolution movies of
fluorescently labeled cells, as Bewersdorf and colleagues
reported in a Nature Methods paper published online in
May. I think back to Toomre’s analogy about trying to
learn the rules of football from a snapshot. At last, a highresolution movie of cells at play. Now scientists can really
learn the rules of the game. /yale medicine
Ashley Taylor is a freelance writer based in New York City.
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can br ain scans
reveal
how we think?
Scientists debate whether such higher-order
processes as consciousness and
morality have their own real estate in the brain.
By Jenny Blair Illustration by Francis Blake

can change their behavior and remain
abstinent, while others fight the battle over and over again. And while
treatment for alcohol abuse is often effective, many patients wind up backsliding. If clinicians knew which ones are most likely to do so, they could
intervene to help them stay sober.
SOME PEOPL E W I T H A LCOHOL ISM

In the not-too-distant future, a clinician in that position
might turn to brain imaging for answers. Using functional magnetic resonance imaging (fMRI), a method
that maps neural activity to specific locations in the
brain, Yale scientist Dongju Seo, Ph.D., and Rajita Sinha,
Ph.D. ’92, Foundations Fund Professor of Psychiatry,
professor of neurobiology, and in the Child Study Center,
examined 45 alcohol-dependent patients and compared
the scans of those who later relapsed to the scans of
those who did not. Surprisingly, when the relapse group
tried to mentally relax, the prefrontal cortex failed to
settle, and during stressful thoughts, it failed to activate,
according to their study in JAMA Psychiatry in May. If
your brain activity looks like that, you’re less likely to
stay sober—or so, apparently, says the scan.
fMRI is the closest we can come to watching the
brain at work. Its vividly colored images seem to offer
snapshots of thought and emotion themselves. The
central tool of many brain researchers at Yale and
around the world, fMRI holds the promise of illuminating the brain-mind connection.

		

Hal Blumenfeld //

“What [fMRI] does is provide
a wonderful initial draft or road
map of structures that could be
		 important and that should
be investigated through
			
other techniques.

’’
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“It provides information that can’t be obtained with
any other approach right now,” said Hal Blumenfeld,
M.D., Ph.D., FW ’98, professor of neurology. The
method is noninvasive and shows the whole brain at
once, with better resolution in time and space than
older methods can offer.
Certainly, fMRI’s ability to peek into our heads
hasn’t been lost on lawyers, advertisers, and entrepreneurs. Brain scan findings have been used in court to
defend sociopaths, while “neuromarketers” have used
fMRI to measure audience reactions to a Harry Potter
movie trailer. A company called No Lie MRI claims to
have developed a reliable lie detector test—or “truth
verification technology”—based on fMRI.
Yet as the technology comes of age, some observers
of the field are calling for caution, and earlier this year
two Yale authors published books arguing that fMRI is
all-too-often misused. In Brainwashed: The Seductive
Appeal of Mindless Neuroscience, co-author Sally Satel,
M.D., HS ’88, a lecturer in the Department of Psychiatry,
examines the implications that our hasty embrace of
fMRI may have for the concepts of free will and human
agency. Amid the popular enthusiasm for brain images,
she argues, misunderstandings abound and dubious conclusions are often drawn. For example, when predicting
an alcoholic patient’s behavior with fMRI findings, she
said, we risk falsely concluding that relapse is inevitable.
In his recent book, Brain Imaging: What It Can
(and Cannot) Tell Us About Consciousness, Robert G.
Shulman, Ph.D., professor emeritus of molecular biophysics and biochemistry, questions whether fMRI
should be used to study such higher-order cognitive
processes as working memory, attention, and consciousness. A biophysicist who pioneered the technique in the
early 1990s, Shulman believes that the design and interpretation of many studies that use it have been faulty. The
brain, he argues, is best studied just like any other organ—
via a physiologic approach that can identify neural

“Mixed-use development”
in the brain
The debate over localization long predates the introduction of fMRI. In the early 19th
century, Franz Joseph Gall, the founder of the now-discredited discipline known as
phrenology, proposed that the brain comprised distinct functional units whose usage
was reflected by bumps in the skull. But when experimental physiologists of that era
tried to confirm this notion by studying brain damage in birds, they failed to find
specific functional losses.
Later, studies of human strokes, the discovery of neurons, and the beginnings
of a distinction between localized symptoms and localized functions continued to fuel
arguments about whether brain functions are discrete and easily mapped.
Some researchers think that the truth lies between the two extremes: simpler functions are localized in modules, or specific areas, while more complex ones are distributed.
“You have some modularity,” said Yale’s Douglas Rothman, Ph.D. ’87, “but the modularity
itself is supported in networks, not in discrete regions completely responsible for complex function.” (Or, as Sally Satel, M.D., and her co-author, Scott O. Lilienfeld, Ph.D., put it, “most neural real
estate is zoned for mixed-use development.”)

processes that are necessary for a person’s behavior.
But many neuroscientists believe that fMRI can
indeed get at higher-order functions—especially when
combined with other measurement methods—and that
research methodologies are improving, reducing the risk
of unwarranted conclusions. They say that Shulman’s
call to limit themselves to neurophysiology and behavior
would do science and patients a disservice.
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pre sen t at t h e c re at i o n

Shulman was among the first physicists to study biological systems with nuclear magnetic resonance, and
by the late 1970s, working at Bell Labs, he was using
it to study how glucose is metabolized in yeast and
muscle. That decade also saw the first magnetic resonance images and the first whole-body MRI scanner.
Improvements in MR technology set the scene for the
development of functional MR imaging at Yale and the
University of Minnesota in 1992 (see sidebar: “BOLD
beginnings,” page 26).
MR imaging had been a major advance in revealing
anatomical structures. Functional MR went a big step

further by mapping brain activity to specific locations
and superimposing that data over the MR image.
It exploits the propensity of hemoglobin to behave
differently in a magnetic field—depending on whether
or not it is oxygenated—a principle called bloodoxygenation-level-dependent (BOLD) imaging. Because
active neurons consume oxygen, the brain compensates
by sending oxygen-rich blood their way; fMRI can map
areas of neuronal function by tracking the flow of oxygenated hemoglobin.
After the initial studies in 1992, scientists rushed
to adopt fMRI, finding it a faster, more accurate, and
more accessible way to image brain activity than such
older technologies as positron emission tomography,
or PET. Early experiments yielded detailed, reproducible maps of brain areas corresponding to sensory and
visual stimulation. The technique has been central to
the advent of cognitive neuroscience, a developing field
that studies the neural basis of higher brain functions.
Cognitive neuroscience studies have implicated the
amygdala, for example, in evaluating threats and mediating emotional learning. Circuits in the hippocampus
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appear to be critically important for relational memory,
which allows us to associate names with faces. Parts of
the prefrontal cortex seem to power down in schizophrenia, and so on. Previous methods had produced a
great deal of information about the functions of these
and other brain areas, but fMRI allowed scientists to ask
more sophisticated questions and clarify what they previously had only suspected was true.
In 2000, for example, investigators at Yale’s Child
Study Center found evidence, through fMRI, that subjects with autism don’t process faces in the brain’s
facial recognition center. Instead, they use an area

of the brain normally associated with recognizing
objects. The finding caused a sensation in the autism
community—it seemed to explain why autistic children tend to show little interest in faces. Their 1997
work followed studies by a group at Yale led by Gregory
McCarthy, Ph.D., and by another group at Harvard
and Massachusetts General Hospital led by Nancy
Kanwisher, Ph.D. She and colleagues including Marvin
M. Chun, Ph.D., now a professor of psychology at Yale,
showed that this brain region—the fusiform face area—
is selectively activated by faces, confirming years of
suggestive but ambiguous data from other methods. It
is today the most-cited fMRI brain research paper in
the scientific literature.

BOLD beginnings
The BOLD effect—tracking neuronal activity
through blood flow—was first demonstrated in
small animals in 1990 by one of Robert Shulman’s
former Bell Labs postdocs, Seiji Ogawa, Ph.D. Then,
Ogawa and another former Shulman postdoc,
Kamil Ugurbil, Ph.D., used the method to produce
the first functional magnetic resonance images
(fMRI) of humans at the University of Minnesota.
Shulman, who was using magnetic resonance
spectroscopy to study metabolic changes in the human
brain, saw an opportunity to get similar information at
much higher spatial and temporal resolution. His Yale postdoc Andrew Blamire, Ph.D., had learned a technique called
echo planar imaging that sped up the process of capturing MR images and was considered critical for exploiting
the potential of the BOLD effect for mapping brain function. Shuman directed Blamire, along with fellow postdoc
Douglas Rothman, Ph.D. ’87, and Terry Nixon, now director
of facilities at Yale’s Magnetic Resonance Resource Center,
to soup up the lab’s outdated MRI system to incorporate the
speed of echo planar imaging.
When Ogawa and Ugurbil heard that the Yale system had
rapid imaging capability, they began a collaboration with
Shulman. This work, which also included Gregory McCarthy,
Ph.D., now a professor of psychology at Yale, led in 1992 to
one of the earliest fMRI studies, the first to show the brain
responding to individual events, in this case a single visual
stimulus. Shulman’s team subsequently collaborated with
McCarthy to perform the first fMRI measurements of a person
performing a cognitive task.

26 yalemedicine.yale.edu

Shulman believes that many fMRI studies are too
ambitious. Mapping brain areas specialized for sensory or motor systems is one thing. Mapping the life of
the mind is quite another. Memory and attention are
subjective processes that cannot be experienced by an
observer, and they may not be as discrete as we think
they are. We talk about remembering to pick up the
kids or remembering a phone number, but those two
acts may not be as fundamentally similar as our single
term for them would imply. “When you start looking
for localization of concepts like honor, values, morality, memory, consciousness, you aren’t going to find
them,” Shulman said, “because we have never learned
exactly what they are.” Shulman points to a UCLA
study purporting to show that Republicans have higher
amygdala activation and are more likely to vote based
on fear and other emotions. Such experiments, he said,
constitute “phrenological fMRI,” a term critics have
used since the early 2000s to dismiss such research.
To grapple with such objections, it’s important to
understand a few things. For one, the brightly colored
images that appear in journals and news reports usually don’t represent one brain at one time; rather, they
represent highly processed, composite results obtained
by processing several individuals’ brain data through
statistical algorithms (see sidebar: “How functional
MRI works,” page 29). Moreover, these algorithms rely
on assumptions not everybody agrees on.
Second, BOLD imaging has important limitations.
Though increased oxygen-rich blood and its stronger
BOLD signal usually flag increased neuronal activity, there’s a time lag, since neurons fire thousands of
times faster than blood flows. Moreover, sometimes the
BOLD signal is positively misleading. Yale’s Blumenfeld
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and his colleagues were the first to show that, in some
seizures, neurons fire in such a frenzy that they need
more oxygen than the brain can deliver and the BOLD
signal goes down instead of up. They also found that
blood flow sometimes declines in response to neuronal
activity. These findings strike at the heart of all BOLD
assumptions. “Taking BOLD alone is always going to
be potentially risky,” said Blumenfeld. “Everyone is
hoping for [better] techniques. ... I’ve been hoping for it
my whole career.”
Third, and perhaps most importantly, experimental
premises are crucial. Cognitive neuroscience assumes
that mental processes like working memory, attention,
problem-solving, and decision-making are real, objective, measurable, observable phenomena. Especially in
the early years of the field, cognitive neuroscientists
believed that these brain functions reside in discrete
modules, a school of thought called localizationism.
Many researchers have come to believe that these functions are organized in networks. Others posit that the
whole brain is involved in all functions—the aggregate
field view (see sidebar: “ ‘Mixed-use development’ in
the brain,” page 25).
These things matter because
they affect how a researcher
plans and interprets experiments. A localizationist who
expects working memory to
reside in one particular spot in
the prefrontal cortex will naturally process his data to look
for that area lighting up. But
there are other ways to analyze
the same data set that can lead
to different conclusions about
which areas of the brain are
active during a cognitive task.
Chun said he believes
that Shulman “has appropriately urged caution over the
years, but his concerns do not
acknowledge all the recent
advances in analysis methods that enable more precise
interpretation of BOLD signal
activity for understanding
perception and cognition.”
As an example, he points to
the work of Jack L. Gallant,
Ph.D. ’86, at UC Berkeley.

ABOVE This graphic highlights areas of the brain
where Yale researchers found significant differences in responses to stress and relaxationinducing stimuli between alcoholic patients and
healthy controls.
BELOW Robert Shulman (left) with Todd Constable
and Douglas Rothman, co-directors of the Magnetic
Resonance Research Center at Yale.
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How functional MRI works
Don’t let that detailed image throw you. Unlike,
say, X-rays, a functional magnetic resonance
image (fMRI) isn’t a snapshot. It’s a statistical map,
the colorful end product of massive calculations.
During an fMRI experiment, researchers typically scan the brain at rest and then during a series
of such tasks as recalling a string of numbers. This
technique yields hundreds of images, each containing information about changes in metabolism
and blood flow. These changes are associated with
neuronal activity, measured in voxels by the tens
of thousands. (A voxel is a cube-shaped data unit
analogous to the 2-D pixel.) Long after the person
being scanned has gone home, the researchers
must contend with gigantic amounts of raw data.
First, in a step called preprocessing, researchers
correct the data. There is slice-timing correction,
since not all “slices” of the brain are imaged simultaneously. There is motion correction, since subjects
tend to move during scans. Low-resolution fMRI data
are superimposed onto a standard “template brain”
image obtained by regular MRI (coregistration), but
these have to be corrected because not everyone’s
brain neatly matches the template (normalization).
Then comes data analysis—researchers try
to isolate those areas and networks that sent
a stronger signal during a specific mental task.
Subtraction is a common approach, in which the
signal obtained at rest is “subtracted” from the
one obtained during the task. To further localize
the mental process being studied, images obtained
during the study task may be subtracted from
images captured during a control task. Whatever

The fMR images in this series show the brain’s
response to changing oxygen levels by overlaying
results from a group of participants in a study of
genetic influences on reading ability. The results
from all 179 subjects were combined into a wholebrain statistical map of areas showing significant
BOLD signal changes.

signal remains may show the area of brain involved
in that task, though this deduction contains many
pitfalls—correlation does not imply causation, and
seemingly simple cognitive tasks may comprise
multiple simpler processes. Yet the signal from a
single task can be extremely faint amid the brain’s
busy baseline activity. Without subtraction the
two scans might look nearly identical.
Combining data from multiple research subjects
is crucial, but it, too, can be dicey. The statistics
may not take into account the anomalies that often
dog complex experiments, such as missing data
or a subject with a truly unusual brain signal. And
individual subjects’ anatomical differences are often
blurred during normalization, which means losing
potentially important information.
Because of an fMR image’s colors, we say that
the brain “lights up” in response to some mental
task. But in reality nothing “lights up”; these colors
are simply a code for the relative strength of the
signal within each voxel. To judge whether that signal is random or real, researchers must also choose
a threshold, or p-value, that represents the likelihood of a particular result being due to chance. A
common p-value in statistics is 0.05, or 5 percent,
meaning that an acceptable result is no more than
5 percent likely to be due to chance alone. But some
fMRI researchers call for p-values as strict as .005,
reasoning that they’ll find fewer false positives that
way. False positives are a real danger, as one group
famously demonstrated by “finding” areas of brain
activation during an fMRI analysis of a dead salmon.
Unfortunately, stricter p-values might eliminate
important data from consideration.
Statisticians are working on ways to refine all
these analyses in hopes of ensuring that what “lights
up” during a cognitive task reflects real, significant,
and specific brain activity. But in the meantime, it’s
best to bear in mind that an fMR image is more like a
graph than a photo. Like any image born of statistics,
it can both enlighten and mislead.
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Gallant’s group has produced highly complex, interactive brain maps, derived from enormous datasets that
attempt to correlate the neocortical activity of study
subjects with hundreds, even thousands of objects and
actions observed by the subjects. The resulting images
and word maps, when viewed dynamically on a computer, are far more nuanced than the 2-D brain slices
that have become familiar since the first fMRI studies
in the early 1990s.

a change of mind

Shulman recalled that shortly after the development of
functional imaging, the idea of modules for memory,
consciousness, and other cognitive concepts raised
hopes that finding where they reside would explain
them at last. “Well,” he said, “that did not work.”
Initially excited by the promise of fMRI to explore cognition, by the mid-1990s he had conducted an experiment that changed his mind. He showed that a certain
region of the frontal cortex lit up during a task of
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actions and objects is organized spatially across the
cortex—but without the 1-to-1 specificity implied
by earlier methods of visualization using fMRI.

working memory. After publishing his results, he realized that he hadn’t demonstrated that this response
was unique. Repeating the experiment with an attention task, he found that the very same area lit up—a
contradiction of the assumption that different mental
activities occupy distinct, nonoverlapping modules in
the brain. At the same time, metabolic studies showed
that even at rest the neuronal activity of the brain is
very high. An absence of change in activity during
a task did not mean a brain region was not involved
in supporting it; instead its activity could just be the
same in the task and control states.
Shulman had committed the reverse inference
error—working backwards to link activity in a brain
region to a specific cognitive function. This error is
one that he and cognitive neuroscientists agree has led
many fMRI researchers to overstate their results. (In
contrast, Chun’s 1997 paper on the fusiform face area
asserted that it is selectively activated by faces, a conclusion drawn after comparison with various control
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Jack Gallant’s lab at UC Berkeley has extended the
boundaries of fMRI visualization by creating an
image viewer that shows how visual perception of

stimuli.) Shulman came to believe that the very philosophical underpinnings of such experiments are shaky,
since they assume a modularity that isn’t neatly borne
out by the findings. Context is all-important: how
working-memory tasks look under fMRI varies widely,
depending on the nature of the task.
A more effective use of fMRI, argues Shulman,
would be to characterize the brain’s activity during
observable behaviors in brain imaging studies. “For
example, the total brain activity necessary for a person to perform the act of memory can be observed,”
he said. “The location of the psychological concept of
memory cannot.”
Critics’ concerns aren’t limited to experimental
method; like Satel, some argue that results are being
exaggerated. In an opinion piece in The New York Times
the authors of the UCLA politics-related study claimed
that fMRI results revealed how 20 voters felt about
Hillary Clinton and Mitt Romney. Exasperated neuroscientists at a dozen universities responded in a letter to
the Times—it’s not possible, they said, to determine a
person’s mental state by looking at a brain scan.
Contrary to hopes, Satel argues, the technology
cannot sway voters, sell products, sniff out lies, or
reveal the causes of crime and mental illness. “To
regard research results as settled wisdom,” she writes,
“is folly.”
Satel views neuroscience and its tools as nothing
short of remarkable. But she thinks that we are too
quick to believe that this young science has at last
illuminated the mind-brain relationship. Our rush to
explain complex behaviors via brain activity alone fails
to take psychological or social factors into account—
and can lead us astray. She is skeptical, for example, of
the way that fMRI findings have been used to argue
that addiction is a purely a brain disease. Moreover,
she writes, “the fact that addiction is associated with
neurobiological changes is not, in itself, proof that
the addict is unable to choose.” Recovery programs
that make use of incentives and consequences work
for addicts, she pointed out, but would never help a
Parkinson patient.

th e b r a i n’s i nt eg r at ed n e t work s

Like psychologist Chun, Marc N. Potenza, Ph.D. ’93,
M.D. ’94, believes that our understanding of brain
organization is outgrowing its initial simplicity.
Potenza is a professor of psychiatry, neurobiology, and
child study who uses fMRI to study behavioral addictions like compulsive gambling.

Conventional wisdom, he said, held until recently
that the amygdala processed fear, the ventral striatum provided drug-induced rewards, and so on. But
these brain regions have been implicated in other processes as well, pushing cognitive neuroscience toward
a network-based model. “The way in which these
regions work together in networks or functionally
integrated activations that some MRI data can identify, that’s really important,” Potenza said. The Human
Connectome Project, in which research universities
share fMRI data on brain networks, is a first attempt at
mapping such connections.
Adoption of a network model isn’t the only shift in
thinking. Researchers are using fMRI results to break
traditional concepts like working memory into such
smaller and more isolable components as encoding,
shifts of attention, and retrieval. They are also studying the default mode network, brain activity when a
person is awake but not doing anything in particular,
using both cognitive and physiological approaches.
There is also brain plasticity to consider. Existing
functional connections in the brain can be readily
altered through learning and experience—and we can
see those changes on fMRI.
Potenza rejects the idea that only behaviors observable by others constitute the proper subject of fmri
study. “There are some conditions like major depression where subjective accounts are very important to
understand,” he said. “If we were to omit looking at
subjective responses, motivational states, emotional
states, we would be limiting ourselves with respect to
our understanding of the human condition in multiple
clinically relevant states.”
Perhaps some of today’s popular fMRI applications
will recede into history, taking their place alongside
early 20th-century electrical healing gadgets and
shoe store X-ray machines. Satel believes this burst
of exuberance, if sometimes troubling, is normal in
these early days of contemporary brain science. “You
start out a little more crude, and then you perfect
and perfect and perfect,” she said. “Wherever we are
in 20 years, I doubt we’d be there had we not gone
through this phase first.” /yale medicine
Jenny Blair, M.D. ’04, a freelance writer based in Austin, Texas, is a
frequent contributor to Yale Medicine.
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said Hampson, whose study was
published online on April 30 in
Translational Psychiatry.
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in the treatment group signifi-
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But when it moves and

In an investigation using
real-time fMRI and neurofeed-
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their own way.”

T O M A S Z W A L E N TA I L L U S T R AT I O N

		 How neurofeedback
helps patients tamp 		
			 down their fears

cantly better at controlling their

When Dennis Spencer (left) began his career in
neurosurgery in the early 1970s, he had two
X-ray technologies at his disposal for brain
imaging. Now, he says, imaging technology
has “revolutionized every field.”

a new vision in the lab
and in the clinic
Since the discovery of X-rays in the 19th century,
new imaging technologies have helped physicians peer into the
causes of disease and provide better clinical care.
By John Dillon

Photos by Robert Lisak

as a neurosurgeon in
the early 1970s, he doesn’t wax nostalgic about the way he imaged a patient’s
brain. “We weren’t that far from Harvey Cushing,” he says, referring to Yale’s
renowned “father of neurosurgery” and X-ray pioneer, who died in 1939.
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Spencer then had two X-ray imaging tools at his disposal. One was angiography, introduced in 1927 but
still widely used, in which an injected dye illuminates
a patient’s blood vessels on X-ray. The other was
pneumoencephalography, a painful invasive procedure
dating back to 1919 that involves draining fluid from
the brain and injecting air into its ventricles to prepare
for an X-ray. “It was a pretty crude field at the time,”
says Spencer, chair and the Harvey and Kate Cushing
Professor of Neurosurgery.
This antediluvian period ended by the mid- to late1970s with the advent of computer-assisted tomography (CAT or CT) X-ray scans, which enabled Spencer to
see blood, soft tissue, and some tumors noninvasively.
Imaging capabilities accelerated in the 1980s with the
development of magnetic resonance imaging (MRI or
MR), which provides even sharper internal images without exposing the patient to radiation; and then positron
emission tomography (PET) imaging, which detects
changes at the cellular level. These and other devices—
boosted by increasingly powerful computers and often
used in combination—have radically improved the detection and treatment of disease.
Today Spencer can remove or stimulate parts of the
brain responsible for intractable Parkinson or epilepsy
and leave vital parts intact. “I can put an electrode within
two millimeters of any part of the brain,” he says.
Yale clinicians and scientists are seizing on the imaging boom to improve patient care. Advanced techniques
have moved from the lab to the clinic and the operating
room and have become key tools for quicker, more accurate diagnoses and better outcomes. Surgeons can now
see inside a patient’s body in three dimensions in real
time while they operate. Imaging technology can identify
the places to avoid during brain surgery, whether a cancerous prostate should be left alone, or whether a breast
mass is normal or cancerous. Imaging modalities can
not only make surgery more precise but may also help a
patient sidestep an operation or biopsy altogether.
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“When I started, I thought I was getting in on the tail
end of the developments of MR,” says R. Todd Constable,
Ph.D., professor of diagnostic radiology. “It turns out,
23 years later, that it hasn’t matured yet.” Constable, a
physicist, is often called on to find the best device (or
devices) for other specialists, and his team uses those
modalities to develop a clinical map of the inside of a
patient’s body. Everyone thought CT scanning “was
done” by 1990, he says, but the development of multidetector, multi-slice imaging extended its warranty.
“There’s still a revolution in imaging for modalities we
discovered years ago that we thought were mature,”
Constable says.

f ro m x-r ay to f m ri

The first great step in medical imaging came in 1895,
when Wilhelm Röntgen took an X-ray of his wife’s
hand, famously displaying her bones and wedding ring.
Cushing, then only 26 and a newly minted M.D., recognized the significance of the device and put X-rays to
clinical use within months. But X-rays went only so far
because they allowed medical professionals to see bones
or teeth but little else.
Ultrasound, which creates images through sound
waves and is familiar to any expectant parent, came
into use in the 1950s. Constable says ultrasound didn’t—
and still doesn’t—deliver clear images, but it has the
advantage of being safe, affordable, and nowadays,
highly portable. The next huge advance came in the
1970s, when the London-based Electric and Musical
Industries developed the CT scan. The CT scan was
the first to deliver X-ray images of the body in cross
sections, and the images could be viewed either as
individual slices of bread or an entire loaf. By the next
decade, MRI, which uses magnetic fields and radio
waves to capture images of internal organs, began providing even clearer shots of soft tissue.
Further breakthroughs in medical imaging came
from unexpected sources—computer graphics and the

film industry. “We can all thank Hollywood and the
gaming industry,” says Xenios Papademetris, Ph.D., an
associate professor of diagnostic radiology, who prepares surgeons for procedures by mapping a patient’s
brain or other body part ahead of time. Graphics cards
were “designed to let kids play games,” he says. “We’re
using them to do other things.”
Constable works with Spencer and other researchers by preparing images for their research or surgical
procedures and says that the technology has made Yale a
leader in providing surgical treatments for patients with
epilepsy who don’t respond to drugs. “Things are moving from the research lab—where we can image these
different aspects of brain function or brain metabolism or what have you—and into the sort of real-time
intraoperative mapping,” Constable explains. When,
for instance, epilepsy patients are being prepared for
surgery, they’ll first get an fMRI. “When you speak in
the magnet, or read, we can isolate your
language cortex,” Constable says. During
an operation, a surgeon can see where that
spot is and knows not to “cut that cortex
because [the patient’s] not going to be able
to speak afterwards.”
Epilepsy is Spencer’s specialty, and the
technology helps him track the origin of
seizures. He’ll cut open a patient’s skull
and—with the help of people like Constable
and Papademetris—implant a grid over the
brain, leaving it there for 10 days while he
monitors brain activity. During that time
the patient’s epilepsy drugs are withdrawn,
and the monitor lets Spencer see which
parts of the brain are initiating seizures.
Information is collated with the patient’s
CT scans to find the problem spot, which
Spencer can locate on the axes of the grid
as a player might do in a game of electronic
Battleship. Electrical stimulation, again
guided by imaging, identifies such critical
function regions as language. He’ll go back
into the patient’s brain and resect diseased
areas, sparing function.
Two operating rooms at Smilow Cancer Hospital at
Yale-New Haven have MRIs specially built for surgery,
including the world’s first combination intraoperative
MRI/endovascular suite. There, Spencer’s neurovascular faculty uses the MRI and a biplane angiography
device that produces 3-D images of the blood vessels in
the brain. He says the improved images have drastically

changed the treatment of brain aneurysms. Ten years ago,
90 percent of arterial bulges were controlled by placing
clips on them. Today, aneurysms are more often secured
internally by coils inserted by a microcatheter—a safer,
less-invasive method—and the use of clips has fallen to
between 30 and 40 percent.

pre v en t i n g fa l se p osit i v e s

While Spencer often uses imaging as a tool during an
operation, Liane Philpotts, M.D., chief of breast imaging at Yale, will happily employ it to prevent a false
positive. In addition to ultrasound and MR, she says that
Yale has the best mammography technology yet: digital
breast tomosynthesis.
Tomosynthesis, approved by the Food and Drug
Administration in 2011 after trials at Yale and four other
medical centers, is the first technology to deliver threedimensional images in mammography. When used in

Liane Philpotts uses digital breast tomosynthesis
to cut down on false positives and make more
accurate diagnoses for breast cancer. Suspiciouslooking images can bring back about one patient
in 10 for more tests—usually false alarms. But,
Philpotts says, “anybody who gets called back
thinks the worst.” Tomosynthesis, which was
approved by the FDA in 2011 after trials at Yale and
other medical centers, is the first technology to deliver three-dimensional images in mammography.
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conjunction with traditional 2-D images, tomosynthesis
cuts down false positives by 30 to 40 percent, Philpotts
says. It has also increased the rate of cancer detection by
up to 20 percent. “Tomosynthesis is a game-changer,”
she says. “It’s a win-win.”
Traditional mammograms can’t always distinguish
cancerous cells from harmless ones. This lack of clarity
is especially problematic in patients—usually younger
women—with dense breasts, which have more glandular
than fatty tissue. “Fat we can see through,” Philpotts
explains. Glandular tissue, however, appears as white on
an image, as do cancer cells. “This is one of the limitations of mammography.”
Philpotts shows the difference in the images of a
patient who underwent both a standard mammogram
and tomosynthesis. The procedures are roughly the same
for the patient: the breast is compressed in the machine
and the 3-D device takes a series of images through
an arc of 15 degrees, which are then reconstructed as
1-millimeter slices instead of just a top or side image of
the entire breast as is done in a routine mammogram.
Philpotts calls up a 2-D image of a whole breast on
one of two adjacent monitors. It shows a mass of white
in the middle. Philpotts is suspicious of the mass but the
image’s blurriness won’t let her draw any conclusions.
She switches the display on the monitor, which then
shows the individual images, like a high-tech zoetrope.
Each slice shows an area deeper within the tissue. “It’s as
if you can see through the breast,” she says. As Philpotts

progresses, she spots a telltale spidery lesion that indicates cancer.
In 2009, the U.S. Preventive Services Task Force
(USPSTF), a group of outside advisors to the Department
of Health and Human Services, recommended that
women over 50 have mammograms every two years
instead of yearly. Citing the cost of false positives and
the radiation younger women are exposed to, the panel
suggested that women in their 40s not get screened
unless they are in a high-risk group. Those recommendations were “controversial,” Philpotts says, conflicting
with those of groups like the American Cancer Society,
which continued to back yearly mammograms for
women between 40 and 49.
Philpotts thinks that 3-D imaging can help bridge the
gap between the conflicting recommendations. A team at
Smilow Cancer Hospital reviewed the mammograms of
14,684 patients and found that the cancer detection rate
was 5.7 per 1,000 patients in those who underwent both
2-D and 3-D screening compared to 5.2 per 1,000 among
those who had only a standard mammogram. Subsequent
ongoing data collection has shown an even greater difference in cancer detection. Moreover, 54 percent of those
whose cancer was detected with the combined imaging
had dense breasts; of those whose cancer was identified
by 3-D imaging only, 21 percent had dense breasts. In
2009, Connecticut became the first state in the nation to
mandate that women be notified if a mammogram shows
that they have dense breast tissue and that their insurance pay for additional screening.
With 3-D imaging, Philpotts said, the
risk of false positives is reduced. “We’re
saving on the costs of unnecessary diagnostic workups and possibly biopsies.”
At the start of her career 20 years ago,
“when you had a finding, you had to go to
the OR,” Philpotts says, but today “very
few patients need to be taken to surgery.”
The 3-D machine can reduce the number
of callbacks, but those who must return
also benefit from better imaging, which
guides doctors through a real-time core

The prostate presents special problems in imaging.
Ultrasound guides clinicians to the prostate but
can’t image tumors, so clinicians use a combination
of MRI and ultrasound to create a 3D model. Peter
Schulam (standing), chair of urology, and clinician
Preston Sprenkle discuss a case with a patient.
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needle biopsy to remove small pieces of dubious tissue.
Ultrasound is used as a complement to mammography
to find the extent of disease, if any, since cancerous cells
appear dark on an ultrasound image. Patients fear a
biopsy, but they’re relieved by the minimal invasiveness
of the procedure.

seei n g w h at c a n’t b e i m ag ed

Improved imaging systems are also helping Yale physicians treat cancers specific to men. Prostate cancer is
even harder to find than cancer of the breast, because the
prostate is the only solid organ in which cancer cannot
be imaged. Ultrasound—the modality that guides clinicians to the prostate—alone cannot see tumors, says Peter
Schulam, M.D., director of the Cancer Center’s Prostate
and Urologic Cancer Program. His team, like those of
other specialists, uses a combination of imaging modalities that work better together than separately.
When Schulam arrived at Yale from UCLA last year, he
recruited a team of doctors, engineers, and radiologists.
He also brought a 3-D imaging navigation system called
the Artemis Device, which he says is the best available to
identify and monitor the progress of prostate cancer.
“Every man with prostate cancer doesn’t need to
be treated,” Schulam says. “The question is: How
do you differentiate?” Prostate cancer kills roughly
30,000 American men every year—more than any
other malignancy except lung cancer, according to the
American Cancer Society. Most men diagnosed with the
disease, however, die of some other cause.
High levels of prostate-specific antigen (PSA) may
signal cancer, but an enlarged but healthy prostate can
also raise PSA levels. In 2012, the USPSTF recommended
against PSA screening for cancer, saying that men are too
often treated when the disease isn’t causing symptoms.
CT scans aren’t beneficial in detecting possible cancer,
so doctors increasingly use MRI. “The problem is that
once you see something suspicious on an MRI, it’s hard
to biopsy” because the powerful magnets prevent the
use of needles, Schulam says. A prostate biopsy is often
educated guesswork, with doctors taking a dozen or so
passes with a 1-millimeter-thick needle into the walnutsized gland. Not only are biopsies often painful procedures and recovery can lead to such complications as
sepsis, but “you can miss cancer,” Schulam says. “Or you
can detect cancer but not know the volume of cancer.”
Because prostate cancer generally progresses very
slowly, treatment options range from radiation or
removal of the prostate to watchful waiting, in which
doctors take no significant action unless the diseased

organ causes problems. Active surveillance—careful
monitoring for signs that the disease is progressing—is
a relatively recent approach that falls somewhere in
between. It is usually recommended for men at low
risk of developing symptoms from the disease. Artemis,
which combines MR and ultrasound images to improve
the detection and treatment of prostate cancer, is the key
tool in the image-guided approach to active surveillance
of the disease.
Artemis uses a multiparametric MRI—which also measures chemical concentrations and blood flow in tissue—
to identify regions of the gland that may be cancerous.
“The machine takes the MRI image and an ultrasound
image and puts them together in a 3-D model,” says
Preston Sprenkle, M.D., a urologist on Schulam’s team.
The real-time ultrasound feature then “helps us guide
where our needles go,” so biopsies aren’t as blind as they
have been in the past.
The team can then determine how diseased the
prostate is through what’s called a Gleason score—
which predicts whether the cancer will grow and
spread to other organs—and what action comes next.
Men with a low Gleason score can prevent or postpone
unnecessary radiation therapy or a prostatectomy,
which can leave patients incontinent or impotent. “If
you lose one or both of those, your quality of life is dramatically changed,” Sprenkle says.
Artemis promotes active surveillance because
it “records exactly where the biopsy was taken from,”
Schulam says. When the team members examine the
gland a second time, they have a superimposed image so
“we can biopsy the exact same place as before. If something changes, you intervene such that you haven’t lost
your window of opportunity to achieve cure.”

a re vo lu t i o n i n e v ery f i eld

Advances in imaging, from X-rays to CT scans to fMRI,
have taken a lot of the guesswork out of diagnosis and
treatment. They have reduced inaccuracies in testing, spared patients anxiety from false positives, and
improved outcomes. Spencer is happy with the progress
he’s seen since his early days when neurosurgical imaging
was in its infancy. “Imaging is important to everything
we do every day,” he says. “It’s revolutionized every field.
Our understanding of the brain—and our understanding
of brain disease and the future of treating it—is just so
tied to our imaging.” /yale medicine
John Dillon, a New Haven-based journalist, has been writing on
health and medical issues for 15 years.
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Brain imaging in
the era of bell bottoms
Arrival of the CT scanner at Yale
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Polaroids or on X-ray film.
“When the first images came

OPPOSITE Side-by-side
images of a CT scan
from the 1970s and a
more recent scan show
how the technology has
advanced.
THIS PAGE Early CT scans
could provide images
only of the head.

neurological diagnoses except
with cerebral angiography or
pneumoencephalography.”
Camputaro, who still manages 3-D CT and MR imaging
at the hospital, says that not
only did CT simplify image
interpretation, but it also
changed how anatomy and
physiology are taught. Since
almost all ER patients are
automatically scanned, and
those scans are available on
the hospital server, students
are now trained with CT
images rather than with textbook images.
Summing up the sea
change, Kier, who is still one
of the hospital neuroradiologists, says, “We went from
painful, dangerous procedures to painless and safe
procedures. Of all the changes
that the diagnosis of neurological disorders has gone
through prior to the modern
era of MRI scanning, the biggest change was at the time
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CT was introduced.”
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From selling used car parts
to studying organ transplants
F RO M T H E T I M E PA RW I Z A B R A H I M I S TA R T E D S C H O O L

until he was

13 or 14, weekend mornings often meant getting up at 1 a.m. to help his
father deliver The Seattle Times. Then, before sunrise, Parwiz and his
brother and two sisters would help their parents load used car parts into
a rickety station wagon to sell what they could at the Midway Swap &

A former refugee from
Afghanistan finds hope in
the American dream and
a career as a physicianscientist.
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“I don’t think my dad really understood labor laws,” said Abrahimi with
a laugh. During the week, his father did odd jobs, and the family lived
in public housing.
In a roundabout way, it was that flea market that set Parwiz Abrahimi
on the road to what he is today: an M.D./Ph.D. student at Yale and a 2013
recipient of a Paul & Daisy Soros Fellowship for New Americans.
Abrahimi and his family came to the United States from Afghanistan
in 1990, when he was four. Fighting against the invading Soviet army
had turned into a civil war a year earlier after the Soviet Union withdrew
its troops from the country. Three of Abrahimi’s uncles had died in the
violence, and his father, who had worked for the previous government,
had twice been arrested. A smuggler led the family—members of the persecuted minority group, the Hazara—through the mountains to Pakistan.
They were granted asylum in the United States 18 months later.
When Abrahimi was 12, his father bought him a manual for the
programming language C++ at the swap meet. As Abrahimi struggled
to learn the program on a clunky Intel “286,” he discovered that “I was
a technical guy.” It opened up the world of quantitative reasoning. The
gift also conveyed a message: that learning was a priority. “We took
the interpretation of the American dream as obtaining an education
and achieving social mobility.”
At the University of Washington, Abrahimi studied biomedical
engineering because it was new and multidisciplinary and addressed
problems in medicine. He graduated in 2007 and worked for a year at
the National Institute on Aging in Baltimore, Md., trying his hand at
laboratory research “to see if it was something for me.” It was.
In 2008, before starting the M.D./Ph.D. program, Abrahimi taught science for a year at the American University of Afghanistan in Kabul and at
Marefat High School in his family’s former home, the impoverished Dashti

C AT H Y S H U F R O P H O T O

Shop in suburban Seattle.

faces

Barchi neighborhood. He moved
to New Haven a year later to
begin his medical studies. Three
years later, before beginning his
doctoral research, he returned to
Afghanistan to study the safety of
donated blood.
Now doing his doctoral
research in the laboratory
of Jordan S. Pober, M.D. ’77,
Ph.D. ’77, professor of immunobiology, Abrahimi is testing
ways to modify foreign proteins
in a transplanted organ so that

			

received one of 30 fellowships,
which provide $90,000 over two
years to fund living expenses
and tuition. Fellowship director Stanley J. Heginbotham said
that Abrahimi stood out for his
achievements in academia and
for “his commitment to moral
solutions in Afghanistan, and his
commitment to transplant medicine. … This guy’s going to make a
real difference in some aspect of
American life.”
In his spare time Abrahimi
serves as a director for social services at the student-run HAVEN
Free Clinic in New Haven. He
envisions a career that combines
care of transplant patients with

Parwiz Abrahimi //

		 “This is a country that took my
family in when we had nothing,
			
and here I am studying at Yale.
they won’t set off alarm bells in
the recipient’s immune system.
Those warning proteins come
from the endothelium, the thin
layer of cells that lines blood
vessels in the organ.
“We want to change the gene
expression of the endothelium
to make it less stimulating to the
immune system,” said Abrahimi.
While most efforts to prevent
rejection focus on dampening
the host’s immune response,
Abrahimi is looking at modifying
the transplanted organ.
Pober describes Abrahimi’s
ability to design and carry out
experiments as “remarkably
well-developed for someone this
early in their graduate training.”
In May the Soros Fellowship
announced that Abrahimi had
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’’

research on transplantation. “My
end goal is to become a physicianscientist, for the clinical care to
inform my research.”
Abrahimi became a U.S. citizen in 1997. “This is a country
that took my family in when
we had nothing, and here I am
studying at Yale,” he said. “That
said a lot about the country, that
it would provide an opportunity
to a person like me. This is a
country of immigrants, and my
generation of Afghan Americans
is slowly being integrated into
this country and is able to contribute back to the society.”
—Cathy Shufro

»

Patience pays off for
Yale neuroscientistturned-inventor

Medical students who’ve studied on an iPhone while waiting in line for a latte have Mark
Williams, Ph.D. ’96, to thank
for helping break the chains that
once bound them to the library.
After completing his Ph.D.
in neuroscience at the School
of Medicine and postdoctoral
research at Duke University,
Williams found that basic science research wasn’t for him.
With interests spanning neuroanatomy, art, design, communications, and business, he asked,
“What’s a career that you can
build from that?”
Somewhere between the
time that a computer cropped
up in every home and a smartphone appeared in every pocket,
Williams found the answer.
He first developed educational
materials on CD-ROM for medical students in the late-1990s.
Eventually he was designing apps
for the video iPod before there
was a way for consumers to buy
such apps. In 2008, when Apple
launched the App Store—the
platform through which iPod
touch and iPhone users now buy
software—four of Williams’ products were among the first 500.
Williams’ company, Modality,
produced two Frommer’s travel
guides, Netter’s Anatomy Flash
Cards and Netter’s Neuroscience
Flash Cards.
Williams’ inspiration came
when he started teaching neuroscience to first-year med students
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at Duke in 1997. He wanted to
tackle an educational challenge.
“How could we reinforce the basic
concepts outside the classroom
so that class time is really about
problem-solving, collaboration, and building relationships
between student and mentor?”
In the late 1990s, at a time
when every textbook came
with a supplemental CD-ROM,
Williams developed a neuroanatomy reference on CD-ROM
through startup company
Pyramis. Users could select
the name of a part of the brain,
see images of it, then slice it
and rotate it in 3-D. “It’s silly
today, but the Internet was only
just emerging. This was a great
way to see an image and learn
where it’s located in the brain,”
Williams said.
Williams left Duke in 2005 to
focus on software development
and to start a company which
eventually became Modality. He
remains in Chapel Hill, where
he continues to develop new
technologies.
As personal technology moved
from the desktop to the palm of
the hand, so did Modality.
When the market shifted
toward digital flashcards, textbooks, and guides, Williams
and his team learned to transform already digitized content
into applications for handheld
devices. They could format any
digital book for use on an iPod.
The only problem was that Apple
did not allow software development for the iPod at this time.
Williams and his team waited

for a day when Apple would recognize their worth.
“That day came. We got the
call,” Williams said. They made
a deal for Modality to sell its
products to video iPod users.
This was in 2007, when users
had to go to an Apple store—in
person—to buy a code on a card
so they could download the app
to their computers and transfer it to their iPods. Droves of
publishers clamored to get onto
the gizmos that their campus
reps were seeing plugged into
the ears of college students
everywhere.
Modality transformed a
number of titles, but Williams
was most excited about medical
illustrator Frank Netter’s products, which are published by
Elsevier. “Netter revolutionized
medical illustration, so when we
could bring that to the iPod, it
was really exciting,” he said.
The users were fans, too.
“A student said to me, ‘Dr.
Williams, I learned five new
brain terms while I was waiting
in line for my latte today.’ ”
In 2008, at the Apple Worldwide Developers Conference,
former Apple CEO Steve Jobs
announced the launch of the
App Store, which allowed users
to download apps directly from
their phones. Onstage beside him
were the dozen developers whose
products would stock the store.
Among them was Williams.
Over the next two years,
Modality launched more than
150 educational apps, including one that allowed users

to cross-reference images in
countless anatomy atlases with
their own CT and MR images.
“Clinicians saw the value of
having their device in the clinic
and showing the anatomy to a
patient. It was a real opportunity for patient engagement.”
In 2012, shortly after
Epocrates bought the company,
Williams left Modality to pursue
projects on his own. He wants
to develop apps to maximize
relationship-building opportunities for patients and doctors
the way his educational software
does for students and teachers.
“Technology should be clearing
the way for these relationships
to take hold,” he said.
—Sonya Collins

online exclusives
A project to build over
the Route 34 Connector reverses an urban
renewal project of the
1960s and vies to bring
two parts of the city
together.
Humility was the word
of the day at the Commencement Ceremony
held May 21 for the
91 members of the
Class of 2013.
An impressive 32 members of the Class of 1963,
along with their guests,
celebrated their 50th
Reunion at the Quinnipiac Club on June 1!
A new scholarship
gives aspiring surgeons
a boost.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our homepage at
yalemedicine.yale.edu.

An alumnus was building
educational apps for the
iPod before Apple was
ready for him. The company finally saw the light.
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question and answer

Ellen Matloff was right—
the Supreme Court said so
ON J U N E

13, 2013, in the case of the Association for Molecular Pathology

v. Myriad Genetics, the United States Supreme Court ruled, in a unanimous decision, that genes cannot be patented. The news was both a shock
and a relief to Ellen T. Matloff, M.S., who started Yale’s Cancer Genetic
Counseling Program in 1995. For 14 years Matloff had argued that something occurring in nature should not merit patent protection and that
the patents were harming patients and medical researchers. When the
watch an interview
with Ellen Matloff at
yalemedicine.yale.edu

American Civil Liberties Union filed a suit against Myriad Genetics, which
held patents on the BRCA1 and BRCA2 genes that are linked to breast and
ovarian cancers, Matloff joined the case as a plaintiff. Two weeks after the
Supreme Court decision, Matloff spoke with Yale Medicine.
How did you get into a
profession that didn’t exist
when you were born?

even cracked open yet. My

I scheduled appointments.

first job out of graduate

They gave me a supply closet

school was doing pediatric

that they had emptied out

I first learned about the field

and adult genetics at SUNY

for my office. Now we have

of genetic counseling when

Upstate Medical Center in

two secretaries, a phle-

I was a sophomore at Union

New York. It was then, in

botomist, and six and a half

College, taking a course

1995, that significant discov-

genetic counselors, and we

in genetics. I enjoyed the

eries began being made in

are still growing.

course so much that I did an

cancer genetics.

internship at Albany Medical

BRCA2 hadn’t been cloned,

genetics was not an option

What has changed since
you started? When the

testing for that condition.

because the field hadn’t

genetic counseling pro-

Patients would come in,

School. At that time, cancer

gram was started in 1995
by Vincent DeVita, who
was director of Yale Cancer
Center, I was everything.
I was the secretary;

{ To nominate a subject for Q&A, contact

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or e-mail ymm@yale.edu
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In 1995, BRCA1 and
so we didn’t have genetic

Q&A WITH

Ellen Matloff
we’d take their family his-

BRCA2 were first discovered,

tory, and determine, based

there were many labs across

on that history, if it looked

the country that were offer-

hereditary. If it did, we

ing testing. We were offer-

would make estimates of

ing testing here at Yale for

their risk to develop cancer.

of genetic testing has gone

three months when BRCA

cost of BRCA testing went up,

down, down, down, yet the

testing became available

very outspoken about the

and the phones were ringing

danger of gene patenting

up, up. Before the patent was

off the hook. With BRCA1

since the late 1990s. I had

overturned, the cost of BRCA

and BRCA2, genetic testing

written many editorials to

testing was $4,000.

really became available to

prestigious medical journals

the masses.

and they told me my letter
weren’t even going to send it

Where were you when you
heard the Supreme Court
decision? The decision came

out for review. I couldn’t get

on my daughter’s last day

anyone to take it seriously.

in preschool, and I went for

Someone suggested I contact

the parent sing-along. It was

a very well-known bioethi-

pouring rain. We ran from

was so preposterous they

With her decision to go
public on her double mastectomy, has Angelina Jolie
done a service to the cause
of genetic counseling? For
a movie star whose liv-

cist, Arthur Caplan, and see

preschool to the car and

ing is based on her body

if I could get him interested

were soaking wet. It was

and her looks, as well as

in becoming a co-author. Lo

then that I heard my cell

her talent, to put this out

and behold, he was inter-

phone going crazy. I had a

there was a really brave

ested. Because of his reputa-

million text messages, and

thing to do. Since the story

tion, we landed the cover of a

they all said the same thing:

broke, our referral rate has

prestigious bioethics medical

unanimous decision by the

increased by 40 percent. A

journal. Later on, when the

Supreme Court banning gene

lot of people have asked me

ACLU decided to sue and was

patents. I started crying. I

if Angelina Jolie made the

looking for plaintiffs, I got a

was shocked and relieved

right choice. This is a very

phone call.

and overwhelmed. For me

individual decision. It var-

this had been a 14-year bat-

Why shouldn’t genes be patented? First of all, patents

tle. To have it go all the way

family history, and personal
preferences. Do I think

are supposed to be protection

have it be a unanimous deci-

Angelina Jolie made a rea-

for innovation. The human

sion were just overwhelm-

ies based on the person, the

John Curtis

$1,600. Over time the cost

How did you get involved in
the Myriad case? I’d been

I’d been at Yale for about

CONDUCTED BY

to the Supreme Court and to

sonable decision? Absolutely.

gene is nothing that was dis-

ing. My 3-year-old daughter

She’s reduced her risks

covered by Myriad Genetics.

was alarmed that mommy

tremendously. She’s reduced

There was nothing new

was crying. I said, “We won

her worry.

invented. Second, we can

today. These are happy tears.”

now see what kind of damage can be done to patients
and researchers if a company
holds the patent to the letter
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of the law. When BRCA1 and
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book review
Risk, Chance,
and Causation
BY

Michael Bracken
PUBLISHED BY

Yale University Press

What should
we believe?
		
In a new book, a public health
professor helps the public understand what’s
behind health reports in the media.
By Cathy Shufro
daily: On the nightly news,

Bracken offers a rem-

leukemia drug worked well

An example from

edy in his new book, Risk,

in monkeys but nearly killed

Bracken’s own research on

six healthy humans.

the effects of early child-

in the newspaper, on blogs,

Chance, and Causation:

and even at parties, we hear

Investigating the Origins

Bracken lays out the

pronouncements about what

and Treatment of Disease.

principles of a good study by

disease illustrates the

to eat, what pill to take,

In this accessible, lively, and

describing one from China

complexity of study design.

which screening test we

often witty book, Bracken

that tested whether women

Does giving antibiotics to

absolutely must schedule—or

explains how epidemiolo-

who examined their breasts

very young children make

might be better off avoiding.

gists understand the world.

for lumps reduced their

them more likely to develop

And what’s recommended

He shows why good study

chance of dying from breast

asthma? Antibiotics might

hood illness on later chronic

one day seems laughable

design is crucial in distin-

cancer. The study enlisted

limit the development of the

the next. So what health

guishing between chance

250,000 women and com-

child’s immune system. On

news should we heed? What

and causation. Bracken dis-

pared a study group (women

the other hand, children

should we ignore?

cusses the reasoning behind

taught self-examination)

prone to asthma may get

ethical guidelines and,

with a control group (women

more antibiotics because

tools to judge, said Michael

surprisingly, explains how

not instructed in self-exam).

they wheeze. Even care-

B. Bracken, M.P.H. ’70,

they can sometimes cause

All were Shanghai textile

ful study design could not

Ph.D. ’74, the Susan

harm. In “Celebrity Trumps

workers living similar life-

totally eliminate uncertain-

Most of us lack the

Dwight Bliss Professor of

Science,” Bracken cites a

styles, which minimized

ties about which came first:

Epidemiology at the School

rock star’s misinformation

influences of other variables.

the antibiotics or the asthma.

of Public Health. “We don’t

about the effects of mari-

The 10-year study found

educate children and adults

juana and an ex-Playboy

that the women trained in

The deluge of health
news will remain relentless,

in anything to do with

bunny’s inaccuracies about

self-exam found more breast

he said. “The 24-hour news

understanding risk or prob-

the cause of autism.

lumps than the controls did,

cycle has to be continually

In addition, Bracken

but deaths from breast cancer

fed. They jump on every-

devotes a chapter to the

were identical in both groups.

thing.” Unless people learn

ability,” Bracken said in a
recent interview.

{ Send notices of new books to

benefits and the limita-

how to evaluate news on their

tions of using animals for

own, he said, “the net effect

research—animals often fail

will be that the real health

as proxies for human beings.

messages get lost in this

For example, a potential

quagmire of misinformation.”
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News about health deluges us

end note

Art and the human body
DU R ING A W EEK IN J U N E

visitors to the Yale School of Art’s Green Gallery were treated to

glass representations of the human anatomy, everything from wombs to gall bladders including this depiction of human fat. The exhibit, “Looking In,” was assembled by physicians, glass
artists, and Reintegrate: Enhancing Collaborations in the Arts and Sciences and coincided with
New Haven’s annual International Festival of Arts & Ideas.
The exhibit closed with a talk by David Yuh, M.D., professor and chief of cardiac surgery at
the School of Medicine, a member of the doctor/artist team. Others on the team included medical student Lucinda Liu; G. Kenneth Haines III, M.D., associate professor of pathology; and glass
artists Michael Skrtic and Daryl Smith, a scientific glassblower in Yale’s chemistry department.
Sinclaire Marber, a student at Yale College, curated the exhibit.
—John Curtis

